Related Experiment Video

Updated: Jun 9, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

389

Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and

Christina Sternberg1,2,3, Martin Raigel4,5,6, Tanja Limberger4,6,7

  • 1Department of Pathology, Medical University of Vienna, Vienna, Austria. christina.sternberg@meduniwien.ac.at.

Molecular Cancer
|November 1, 2024
PubMed
Abstract

Insights

Activating IL6ST/STAT3 signaling in prostate cancer induces senescence and attracts immune cells, hindering tumor growth. This suggests IL6ST activation, not blocking, may be a novel therapeutic strategy for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Prostate cancer is a leading global cancer in men.
  • IL6ST/STAT3 signaling is implicated in various cancers, but its role in prostate cancer is unclear.

Purpose of the Study:

  • To investigate the role of IL6ST signaling in prostate cancer development and progression.
  • To explore the potential of IL6ST/STAT3 as a therapeutic target.

Main Methods:

  • Constitutive activation of IL6ST signaling in a Pten-deficient mouse model.
  • Analysis of IL6ST expression in human prostate cancer cohorts.
  • Transcriptomic and multiplex histopathological analyses.

Main Results:

  • IL6ST activation in prostate epithelial cells triggers STAT3 signaling, leading to senescence via the STAT3/ARF/p53 axis.
  • IL6ST activation promotes cytotoxic T-cell recruitment, impeding tumor progression.
  • High IL6ST mRNA in patients correlates with better survival, increased senescence, and an immune-hot tumor microenvironment.

Conclusions:

  • IL6ST/STAT3 signaling has a context-dependent, tumor-suppressive role in prostate cancer.
  • IL6ST activation induces senescence and immune cell attraction, opposing tumor growth.
  • Cell-autonomous IL6ST activation presents a novel therapeutic strategy, challenging current blockade approaches.
Keywords:
Cytotoxic T-cellsIL6ST/STAT3 signalingImmune cell infiltrationL-gp130Prostate cancerSenescenceSenescence-associated secretory phenotypeTumor microenvironment

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.4K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K